Extracellular vesicles from hair follicle-derived mesenchymal stromal cells: isolation, characterization and therapeutic potential for chronic wound healing.
Chronic wounds
Diabetic ulcers
Exosomes
Extracellular vesicles
Hair follicle
Mesenchymal stromal cells
Microvesicles
Skin wounds
Journal
Stem cell research & therapy
ISSN: 1757-6512
Titre abrégé: Stem Cell Res Ther
Pays: England
ID NLM: 101527581
Informations de publication
Date de publication:
08 04 2022
08 04 2022
Historique:
received:
22
02
2022
accepted:
23
03
2022
entrez:
9
4
2022
pubmed:
10
4
2022
medline:
13
4
2022
Statut:
epublish
Résumé
Mesenchymal stromal cells (MSCs) and their extracellular vesicles (MSC-EVs) have demonstrated to elicit immunomodulatory and pro-regenerative properties that are beneficial for the treatment of chronic wounds. Thanks to different mediators, MSC-EVs have shown to play an important role in the proliferation, migration and cell survival of different skin cell populations. However, there is still a big bid to achieve the most effective, suitable and available source of MSC-EVs. We isolated, characterized and compared medium-large EVs (m-lEVs) and small EVs (sEVs) obtained from hair follicle-derived MSCs (HF-MSCs) against the gold standard in regenerative medicine, EVs isolated from adipose tissue-derived MSCs (AT-MSCs). We demonstrated that HF-EVs, as well as AT-EVs, expressed typical MSC-EVs markers (CD9, CD44, CD63, CD81 and CD105) among other different functional markers. We showed that both cell types were able to increase human dermal fibroblasts (HDFs) proliferation and migration. Moreover, both MSC-EVs were able to increase angiogenesis in human umbilical vein endothelial cells (HUVECs) and protect HDFs exposed to a hyperglycemic environment from oxidative stress and cytotoxicity. Taken together, HF-EVs demonstrated to exhibit comparable potential to that of AT-EVs as promising candidates in the treatment of chronic wounds.
Sections du résumé
BACKGROUND
Mesenchymal stromal cells (MSCs) and their extracellular vesicles (MSC-EVs) have demonstrated to elicit immunomodulatory and pro-regenerative properties that are beneficial for the treatment of chronic wounds. Thanks to different mediators, MSC-EVs have shown to play an important role in the proliferation, migration and cell survival of different skin cell populations. However, there is still a big bid to achieve the most effective, suitable and available source of MSC-EVs.
METHODS
We isolated, characterized and compared medium-large EVs (m-lEVs) and small EVs (sEVs) obtained from hair follicle-derived MSCs (HF-MSCs) against the gold standard in regenerative medicine, EVs isolated from adipose tissue-derived MSCs (AT-MSCs).
RESULTS
We demonstrated that HF-EVs, as well as AT-EVs, expressed typical MSC-EVs markers (CD9, CD44, CD63, CD81 and CD105) among other different functional markers. We showed that both cell types were able to increase human dermal fibroblasts (HDFs) proliferation and migration. Moreover, both MSC-EVs were able to increase angiogenesis in human umbilical vein endothelial cells (HUVECs) and protect HDFs exposed to a hyperglycemic environment from oxidative stress and cytotoxicity.
CONCLUSIONS
Taken together, HF-EVs demonstrated to exhibit comparable potential to that of AT-EVs as promising candidates in the treatment of chronic wounds.
Identifiants
pubmed: 35395929
doi: 10.1186/s13287-022-02824-0
pii: 10.1186/s13287-022-02824-0
pmc: PMC8994406
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
147Informations de copyright
© 2022. The Author(s).
Références
Pharmacol Res. 2008 Aug;58(2):165-71
pubmed: 18617006
Int J Mol Sci. 2020 Apr 13;21(8):
pubmed: 32295047
Dermatol Surg. 2008 Nov;34(11):1577-9
pubmed: 18798745
Nat Commun. 2019 May 27;10(1):2331
pubmed: 31133680
Cells. 2019 May 16;8(5):
pubmed: 31100937
Cytotherapy. 2015 Aug;17(8):1036-51
pubmed: 25981558
Front Cell Dev Biol. 2021 Jul 20;9:713605
pubmed: 34354997
Cell Death Dis. 2016 Jun 23;7(6):e2277
pubmed: 27336721
Semin Thromb Hemost. 2018 Mar;44(2):142-150
pubmed: 28905351
Blood. 2010 May 6;115(18):3843-51
pubmed: 20185588
J Invest Dermatol. 2008 May;128(5):1196-206
pubmed: 18160967
Sci Adv. 2021 Feb 12;7(7):
pubmed: 33579698
Biomater Adv. 2022 Apr;135:212738
pubmed: 35929212
Pharmaceutics. 2021 Oct 27;13(11):
pubmed: 34834217
Biomedicines. 2022 Jan 24;10(2):
pubmed: 35203464
Theranostics. 2019 Jan 1;9(1):65-76
pubmed: 30662554
Stem Cells. 2014 Jun;32(6):1408-19
pubmed: 24578244
Stem Cells Dev. 2015 Jul 15;24(14):1635-47
pubmed: 25867197
Stem Cells Transl Med. 2017 Mar;6(3):736-747
pubmed: 28297576
Int Wound J. 2017 Feb;14(1):89-96
pubmed: 26688157
Mol Biol Rep. 2021 May;48(5):4527-4535
pubmed: 34145535
J Extracell Vesicles. 2019 Aug 27;8(1):1635420
pubmed: 31497264
Circ Res. 2017 May 12;120(10):1658-1673
pubmed: 28495996
Sci Rep. 2021 Jan 13;11(1):1053
pubmed: 33441764
J Extracell Vesicles. 2019 Jun 17;8(1):1626654
pubmed: 31258880
J Invest Dermatol. 2008 Oct;128(10):2526-40
pubmed: 18449211
Stem Cell Res Ther. 2020 May 11;11(1):174
pubmed: 32393338
Cell Death Dis. 2011 Jul 28;2:e186
pubmed: 21796158
Adv Drug Deliv Rev. 2021 Aug;175:113775
pubmed: 33872693
J Transl Med. 2015 Sep 19;13:308
pubmed: 26386558
Stem Cell Res Ther. 2020 Jun 8;11(1):225
pubmed: 32513263
Biomaterials. 2020 Aug;249:120020
pubmed: 32305816
Front Physiol. 2016 Feb 09;7:24
pubmed: 26903875
Adv Drug Deliv Rev. 2021 Dec;179:114001
pubmed: 34673131
J Extracell Vesicles. 2021 Aug;10(10):e12129
pubmed: 34377375
Stem Cell Res Ther. 2019 Nov 28;10(1):359
pubmed: 31779700
Front Immunol. 2019 Mar 12;10:446
pubmed: 30915084
Nat Methods. 2017 Feb 28;14(3):228-232
pubmed: 28245209
Cells. 2019 Aug 13;8(8):
pubmed: 31412678
Nat Commun. 2021 Jul 19;12(1):4389
pubmed: 34282141
J Extracell Vesicles. 2021 Sep;10(11):e12137
pubmed: 34478241
Adv Drug Deliv Rev. 2018 Apr;129:394-406
pubmed: 29408181
Mol Cancer. 2010 Nov 23;9:301
pubmed: 21092273
J Biomed Mater Res A. 2020 Mar;108(3):545-556
pubmed: 31702867
J Extracell Vesicles. 2019 Jan 20;8(1):1565885
pubmed: 30719241
Science. 2020 Feb 7;367(6478):
pubmed: 32029601
J Extracell Vesicles. 2019 May 28;8(1):1615820
pubmed: 31191831
Stem Cell Res Ther. 2019 Jun 3;10(1):158
pubmed: 31159859
Front Immunol. 2017 Jul 24;8:892
pubmed: 28791027
Adv Exp Med Biol. 2019;1084:187-206
pubmed: 31175638
Thromb Haemost. 2005 Aug;94(2):432-7
pubmed: 16113836
Dis Model Mech. 2014 Nov;7(11):1205-13
pubmed: 25359790
J Anat. 2021 May;238(5):1203-1217
pubmed: 33372709
Stem Cell Res Ther. 2020 Jan 3;11(1):13
pubmed: 31900239
J Control Release. 2020 Dec 10;328:532-550
pubmed: 32971198
Wound Repair Regen. 2009 Jan-Feb;17(1):1-18
pubmed: 19152646
Signal Transduct Target Ther. 2020 Aug 11;5(1):148
pubmed: 32782280
Theranostics. 2017 Jan 1;7(2):270-284
pubmed: 28042333
Int J Mol Sci. 2021 Mar 19;22(6):
pubmed: 33808520
Stem Cell Res Ther. 2019 Jan 31;10(1):47
pubmed: 30704535
J Biol Chem. 1998 Jun 12;273(24):14827-37
pubmed: 9614084
PLoS One. 2018 Feb 14;13(2):e0191616
pubmed: 29444190
J Invest Dermatol. 2004 Feb;122(2):433-42
pubmed: 15009727
Cell Death Discov. 2019 Mar 19;5:79
pubmed: 30911413
World J Stem Cells. 2020 Jun 26;12(6):462-470
pubmed: 32742563
Stem Cell Rev Rep. 2013 Aug;9(4):451-60
pubmed: 23242965
J Extracell Vesicles. 2018 Nov 23;7(1):1535750
pubmed: 30637094
J Clin Med. 2019 Jun 15;8(6):
pubmed: 31208047
J Extracell Vesicles. 2021 Oct;10(12):e12156
pubmed: 34669269
Int J Pharm. 2018 Dec 1;552(1-2):328-339
pubmed: 30308270
J Extracell Vesicles. 2021 Oct;10(12):e12152
pubmed: 34596354
Wound Repair Regen. 2003 May-Jun;11(3):172-6
pubmed: 12753597
Iran J Basic Med Sci. 2017 Jun;20(6):662-675
pubmed: 28702144
Science. 1997 Apr 4;276(5309):75-81
pubmed: 9082989
Cell Prolif. 2021 Mar;54(3):e12993
pubmed: 33458899
J Extracell Vesicles. 2021 Sep;10(11):e12140
pubmed: 34520123
Sci Adv. 2020 Feb 26;6(9):eaax3223
pubmed: 32133394
Proc Natl Acad Sci U S A. 2006 Apr 11;103(15):5941-6
pubmed: 16585503
Biomedicines. 2019 Apr 08;7(2):
pubmed: 30965624
Sci Transl Med. 2019 May 15;11(492):
pubmed: 31092696
Biomed Res Int. 2018 Jan 30;2018:8545347
pubmed: 29662902
Int J Mol Sci. 2021 Apr 08;22(8):
pubmed: 33917759
Exp Dermatol. 2021 Apr;30(4):512-521
pubmed: 33006790
Cells. 2020 Apr 16;9(4):
pubmed: 32316248
Dev Cell. 2017 Nov 20;43(4):387-401
pubmed: 29161590
Cell Mol Immunol. 2018 Dec;15(12):1071-1073
pubmed: 30275534
Adv Healthc Mater. 2022 Mar;11(5):e2002070
pubmed: 33870645
Regen Med. 2010 Jan;5(1):121-43
pubmed: 20017699
Int J Mol Sci. 2020 Jul 05;21(13):
pubmed: 32635660
Biol Cell. 2017 Feb;109(2):81-93
pubmed: 27730650
J Struct Biol. 2020 Apr 1;210(1):107474
pubmed: 32032755
Front Immunol. 2014 Oct 21;5:525
pubmed: 25374572